IO recession procedures are self-grading

Article

Both inferior oblique (IO) recession in the primary position and in contralateral gaze are largely self-grading and there were no significant differences at three months postoperatively, states an investigation.

Both inferior oblique (IO) recession in the primary position and in contralateral gaze are largely self-grading and there were no significant differences at three months postoperatively, states an investigation.

A group managed by Dr Jun Ho Yoo, Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea, retrospectively studied the records of 43 patients with IO muscle overaction linked to congenital unilateral superior oblique palsy.

The study group consisted of 17 patients who had a unilateral 10 mm recession and 26 patients who had a standard 14 mm recession who were assessed at three months postoperatively. Preoperative hyperdeviation minus postoperative hyperdeviation was used to measure the effect of the recession.

Average preoperative hyperdeviation was 13.4 ± 4.83 prism dioptres (PD) and 16.2 ± 6.32 PD in primary position and contralateral gaze, respectively in the 10 mm group. In the 14 mm group it was 8.0 ± 3.48 PD in primary position and 12.76 ± 4.55 PD in contralateral gaze.

Average hyperdeviation three months postoperatively was 2.1 ± 3.03 and 2.6 ± 3.95 PD in the 10-mm group in primary position and contralateral gaze, respectively. For the 14 mm group it was 0.8 ± 1.21 and 1.8 ± 1.95 PD for primary position and contralateral gaze, respectively.

To read the abstract please go to the latest edition of the Journal of Paediatric Ophthalmology & Strabismus.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.